Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; iron oxide yellow; hypromellose; titanium dioxide; purified talc; macrogol 4000; macrogol 400 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; lactose monohydrate; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide red; macrogol 4000; iron oxide black; macrogol 400 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; purified talc; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; sodium starch glycollate type a; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; purified talc; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.